LUXEMBOURG, March 22, 2016 /PRNewswire-iReach/ -- Advanced Biological Laboratories (ABL) S.A. today announced it has signed an international distribution agreement granting Thermo Fisher Scientific the right to distribute* the ABL ViroScore® Suite and DeepChek® virology sequencing analysis software for Sanger and next-generation sequencing (NGS), respectively. The software is compatible with Applied Biosystems® genetic analysis and Ion Torrent NGS systems and available through the Thermo Fisher Cloud.
Laboratories considering automation to standardize their virology research can now rely on this comprehensive solution coupled with the automation expertise of ABL in virology. Such computerization with local server installation, dedicated bioinformatics pipelines and integration with laboratory information system, helps manage heavy workloads.
ViroScore® and DeepChek® applications help analyse customers' datasets, both Sanger and NGS, and synchronize from sequencing platforms to the Cloud.
"More and more, laboratories are being asked to deliver best-in class solutions, meeting high quality requirements of their competence authorities, at the lower costs. This comprehensive end-to-end solution is ideal for laboratories who seek to consolidate their operations, while enhancing the quality of their results," said Dr Chalom Sayada, CEO at ABL. "The excellent performances of our ViroScore® and DeepChek® downstream analysis software, which are ideally suited for lab automation, will be further enhanced through this distribution agreement, either with local integration to sequencing platforms or through the cloud ecosystem of applications and computing."
"This new agreement marks an important expansion of our Laboratory Software segment," said Dr Sayada. "We are excited to continue developing additional modules, both for Sanger and NGS, parallel to our DeepChek® SingleRound Reagents segment, which shall offer maximally an optimized chain of value in the field of virology."
Using ViroScore® and DeepChek®, laboratories can track viral populations and identify changes within genomes, as well as the expression of dual infections and co-infection. The full informatics workflow takes only a few minutes to complete for each sample.
* Spain, China and Japan are excluded
** Thermo Fisher Scientific reagents and sequencing platforms are for Research Use Only
*** Thermo Fisher Cloud platform is for Research Use Only
Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ and the DPM which are used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL's products also received CE-marking for IVD use. ABL's products, ViroScore® Suite and DeepChek®, are for research use only in the United States, and the upcoming data processing module is a FDA registered class I medical device. ABL's products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions for sequencing, clinical genotyping and drug resistance analysis, including powerful fully integrated databases and analysis systems that combe standard and high-throughput Next Generation Sequencing data. ABL's DeepChek® SingleRound HIV and Hepatitis C Virus (HCV) Genotyping and Sequencing assays are the first two in its virology reagents portfolio. These are currently available for Research Use Only.
Media Contact: Dr Chalom Sayada, Advanced Biological Laboratories, +35226389676, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Advanced Biological Laboratories